February 9, 2016
Phase 1 Study of Second Generation Non-Viral CD19-Specific CAR T-Cell Therapy for Advanced Lymphoid Malignancies
ZIOPHARM Oncology, a biopharmaceutical company focused on new cancer immunotherapies. They announced that the first patient has been enrolled in a Phase 1 clinical study of its second generation non-viral CD19-specific chimeric antigen receptor (CAR) modified T-cell therapy in patients with advance lymphoid malignancies. The CD19-specific T cells were modified using the Sleeping Beauty system to stably express the CAR in T cells.
February 9, 2016
New Data Support the Continued Development of Both CMB305 and G100
Immune Design a clinical-stage immunotherapy company focused on oncology, reported positive topline data from three ongoing Phase 1 oncology studies that support continued development of its two primary in vivo immuno-oncology product candidates, CMB305 and G100. CMB305 is a First-in-class Prime-boost Immunotherapy Targeting NY-ESO-1 Tumors. G100 is an Intratumoral Administration of aTLR4 Agonist Significantly Modifies the Tumor Microenvironment (TME) and Maintains Clinical Benefit.
February 1, 2016
Lion Biotechnologies Announces Allowance of IND Application TO Begin Clinical Trials in CERVICAL, HEAD and NECK Cancers
Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), announced that the US Food and Drug Administration (FDA) has allowed its investigational new drug (IND) application to conduct clinical trials of LN-145 in the treatment of cervical cancer, and head and neck squamous cell carcinoma (HNSCC). Each of the single-arm studies will be conducted at up to six sites in a total of 10 patients with either recurrent or metastatic HNSCC, or recurrent or metastatic cervical carcinoma. The objectives of the studies are to assess safety, tolerability and various indicators of efficacy.
January 31, 2016
The synNotch solution: a next-gen T-cell immunotherapy
This new approach is a new receptor: synNotch. Taking a cue from nature, which relies on a sensor called Notch to perform key functions, the synthetic biology engineers say they can add a receptor that includes one section that sticks out from the cell with one that lies inside. By tinkering with synNotch they can reengineer the immune cell to run down a particular cancer cell target and then issue instructions to turn genes on or off to set up the other half of the therapeutic equation.
January 22, 2016
NewLink Genetics Presents Phase 1b Data of Indoximod in Combination with Gemcitabine/Nab-Paclitaxel for Patients with Metastatic Pancreatic Cancer
Indoximod is an orally available small molecule that has shown the potential to interfere with multiple targets within the indoleamine 2, 3-dioxygenase (IDO) pathway. It is designed to be used in combination with other therapeutic agents to maximize the body’s immune response against a range of tumor types. This combination immunotherapeutic approach was well tolerated and shows encouraging durable responses with a delayed pattern and a 42 percent objective response rate, including one complete response (CR), according to data presented at the 2016 Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco.
January 11, 2016
AstraZeneca and Moderna Therapeutics announce new collaboration to co-develop and co-commercialise immuno-oncology mRNA therapeutics™
This collaboration will combine MedImmune’s protein engineering and cancer biology expertise with Moderna’s mRNA platform. mRNA-based therapies are an innovative treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.
December 8, 2015
Phase 1/2 Study of Varlilumab in Combination with Atezolizumab in Renal Cell Carcinoma
Celldex Therapeutics, Inc. announced the initiation of an open-label, Phase 1/2 safety and tolerability study examining the investigational combination of varlilumab and Roche’s atezolizumab (MPDL3280A) in patients with unresectable stage III or IV renal cell carcinoma (RCC). Varlilumab is Celldex’s fully human monoclonal agonist antibody that binds and activates CD27, a critical co-stimulatory molecule in the immune activation cascade. Atezolizumab is designed to target PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, preventing PD-L1 from binding to PD-1 and B7.1 on anti-tumor T cells. By inhibiting PD-L1, atezolizumab may enable the activation of anti-tumor T cells. These two antibodies are part of a new class of investigational medicines known as cancer immunotherapies.
December 5, 2015
Merck And Amgen Form Partnership For Combo Immunotherapy Cancer Trials
Merck (NYSE:MRK) and Amgen (NASDAQ:AMGN) stated that they are coming together as a partnership, to tackle against a cancer known as Non-Hodgkin’s Lymphoma — NHL. This NHL cancer, is a type of cancer that starts in the lymphatic system or white blood cells of the patient. From there the cells start to mutate into cancer and spread throughout the body. The first trial both companies are starting is a phase 1b/3 study that will combine Amgen’s BLINCYTO in combination with Merck’s KEYTRUDA to tackle against NHL. Both of these compounds have already been approved by the FDA to treat a wide variety of cancers.
November 17, 2015
Two Leading Cancer Nonprofits Join Forces to Tackle Colorectal Cancer with Immunotherapy
A groundbreaking collaboration is under way between Fight Colorectal Cancer (Fight CRC) and the Cancer Research Institute (CRI) to jumpstart this research, thanks to a generous donation in memory of Gordon Cole. On December 2, the two organizations will bring together over 20 global experts in immunotherapy, GI oncology and basic science in New York City for a discussion on the current state of science and the future direction of immunotherapy research for colorectal cancer therapies.
November 5, 2015
INO-3112 Shows Robust Immune Responses in Patients With Head & Neck Cancer
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced an interim data analysis showing that its INO-3112 DNA-based immunotherapy generated specific T-cell responses and was well tolerated in all evaluable patients with head and neck cancer associated with human papillomavirus (HPV) types 16 and 18. The immunology results show that INO-3112 generated robust HPV16/18 specific CD8+ T cell responses and antibodies against HPV16/18 in all 10 tested patients who received all treatments.
igeahub 
2 thoughts on “Immuno-Oncology Upcoming Immunotherapies”